6533b7ddfe1ef96bd1273c6a

RESEARCH PRODUCT

A phase I/Ib study evaluating GDC-0077 (inavolisib) + palbociclib (palbo) + fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)

Katie HutchinsonN. TurnerCristina SauraIan E. KropErika HamiltonPhilippe L. BedardMafalda OliveiraStephanie Royer-jooJennifer L. SchutzmanKevin KalinskyPeter SchmidValentina GambardellaPiia ThomasAndreea VargaGuiyuan LeiAndrés CervantesAntoine ItalianoDejan JuricKomal Jhaveri

subject

FulvestrantHormone receptorbusiness.industryMutantHER2 negativeCancer researchmedicineIn patientPalbociclibmedicine.diseasebusinessMetastatic breast cancermedicine.drughttps://doi.org/10.1055/s-0041-1730220